|
Sep 8
|
Why CymaBay, With 159% Growth This Year, Just Surged For A Second Day Running
|
|
Sep 8
|
CymaBay (CBAY) Stock Up on Positive Results From PBC Study
|
|
Sep 8
|
Why CymaBay Therapeutics Stock Is Jumping Today
|
|
Sep 7
|
CymaBay's Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary Cholangitis
|
|
Sep 6
|
CymaBay to Host Investor Call to Share Topline Results from the Phase 3 RESPONSE Trial of Seladelpar in Primary Biliary Cholangitis on September 7, 2023
|
|
Aug 28
|
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jul 17
|
Recent Price Trend in CymaBay Therapeutics Inc. (CBAY) is Your Friend, Here's Why
|